Antrodia cinnamomea triterpenoids attenuate cardiac hypertrophy via the SNW1/RXR/ALDH2 axis Authors: Yinghua Ma, Yunxia Wang, Gulinigaer Anwaier, Nuerbiye Tuerdi, Yangchang Wu, Yinyue Huang, Boyang Qin, Haoyue Ma, Qiao Zhang, Dalei Wu, Kewu Zeng, Rong Qi Published: 2024 ABSTRACT AbstractAldehyde dehydrogenase 2 (ALDH2), a pivotal enzyme in the metabolism of toxic aldehydes produced by oxidative stress, has been demonstrated to play a cardioprotective role in cardiovascular diseases. Antrodia cinnamomea triterpenoids (ACT) is a medicinal mushroom with anti-inflammatory and antioxidant properties, and our previous study found that ACT can exert anti-fatty liver effects by regulating ALDH2. This study aimed to elucidate the impact of ACT and its monomer on cardiac hypertrophy and investigate the relationship between its pharmacological mechanism and ALDH2. Through examining cardiac morphology and expression levels of hypertrophic biomarkers, ACT significantly reduced myocardial hypertrophy induced by angiotensin II (Ang II) and transverse aortic constriction (TAC)surgery in wild-type mice, but not in ALDH2 knockout mice. In vitro, ACT and its monomeric dehydrosulphurenic acid (DSA) inhibited the hypertrophic phenotype of Ang II-stimulated neonatal cardiac myocytes (NRCMs) in an ALDH2-dependent manner. Regarding the pharmacological mechanism, it was observed that ACT and DSA restored ALDH2 expression and activity in myocardial tissues of WT-Ang II/TAC mice and Ang II-induced NRCMs. Furthermore, it inhibited oxidative stress and improved mitochondrial quality control (MQC) homeostasis in an ALDH2-dependent manner. We screened SNW1, a transcriptional coactivator, as a DSA-binding protein by “target fishing” and cellular enthusiasm transfer assay techniques and validated that SNW1 promoted ALDH2 transcription and translation levels through synergistic interaction with the transcription factor RXR. In conclusion, the findings demonstrate that ACT/DSA upregulates ALDH2 expression via regulating SNW1/RXR, thereby inhibiting oxidative stress and maintaining MQC homeostasis, and then protects against cardiac hypertrophy.Keywords: Cardiac hypertrophy, Antrodia cinnamomea triterpenoids, Dehydrosulphurenic acid, Acetaldehyde dehydrogenase 2, SNW domain containing 1, Oxidative stress and mitochondrial quality control Introduction Cardiac hypertrophy represents a significant adaptive response to pathological stimuli, including hypertension, myocardial infarction, pressure overload, and activation of the renin-angiotensin system [1]. This process is characterized by several key features, including increased cell volume and myocardial mass, elevated protein synthesis, and the activation of fetal genes, accompanied by aberrant collagen deposition [2]. Although an early hypertrophic response can help maintain cardiac function, persistent hypertrophy can lead to further disease progression and worsening of heart failure, one of the world's most common and deadly diseases for which there is still no cure at all [3]. The inhibition or reversal of myocardial hypertrophy and subsequent maladaptive myocardial remodeling is the mainstay of heart failure treatment. Mitochondria are highly dynamic organelles that not only act as the cellular powerhouse, generating most of the chemical energy (adenosine-5-trisphosphate, ATP) required to maintain cellular activity through oxidative phosphorylation and fatty acid oxidation but are also involved in the regulation of a wide range of cellular processes, including pathways such as reactive oxygen species (ROS) generation and maintenance, phospholipid biosynthesis, intracellular Ca2+ regulation, angiogenesis and innate immune signaling [4]. Cardiac hypertrophy is usually associated with mitochondrial dysfunction, and maintaining mitochondrial homeostasis and function are essential for the normal physiology of a healthy heart [5]. To prevent mitochondrial dysfunction, cardiomyocytes maintain mitochondrial homeostasis and meet energy demands by modulating the mitochondrial quality control (MQC) system, which alters mitochondria's shape, structure, number, and intracellular localization [6]. MQC consists of several processes: prevention of mitochondrial oxidative damage, mitochondrial fusion and fission, and elimination of damaged mitochondria by mitophagy [7]. Several studies have shown that damage to MQC leads to a variety of pathological changes, including cardiac hypertrophy and heart failure [8]. The antioxidant defense system in mitochondria plays a crucial role in preventing the excessive production of ROS, which is essential for maintaining optimal ATP production and normal mitochondrial functioning. Although ROS in cells can act as signaling molecules, mitochondrial oxidative stress occurs when high levels of ROS production exceed the capacity of the cellular antioxidant defense system to remove them. This results in the fragmentation of mtDNA and subsequent mitochondrial dysfunction [9]. Evidence indicates that mitochondrial oxidative stress promotes myocardial hypertrophy, fibrosis, and apoptosis [10]. This suggests that inhibiting oxidative stress is a key strategy for ameliorating cardiac hypertrophy. The balance between mitochondrial fusion and fission is critical for normal cardiomyocyte function and this process is controlled by a group of fusion and fission proteins, of which Mfn1, Mfn2, and OPA1 are responsible for mitochondrial membrane fusion, whereas Drp1, FIS1, and MFF mediate fission. Mitochondrial fission is known to be involved in the pathogenesis of cardiac hypertrophy and mitochondrial fusion prevents cardiac hypertrophy [11]. The upregulation of Drp1 expression was observed in cardiomyocytes and transverse aortic constriction (TAC) surgery-induced cardiac hypertrophy in animals, which increased mitochondrial fission and decreased mitochondrial function [12]. Knock-down Drp1 could inhibit norepinephrine-induced mitochondrial fission and cardiomyocyte hypertrophy. In addition, combined ablation of Mfn1/Mfn2 in adult cardiomyocytes causes mitochondrial fragmentation and dysfunction, leading to eccentric hypertrophy and lethal dilated cardiomyopathy [13]. Another key mechanism of MQC is the process of mitochondria-specific autophagy, mainly mediated by the Pink1-Parkin pathway. Previous studies have shown that cardiac-specific overexpression of Pink1 improved cardiac function, attenuated pressure overload-induced cardiac hypertrophy, and facilitated myocardial mitophagy in TAC mice, suggesting that Pink1 may play a protective role in cardiac hypertrophy [14]. Acetaldehyde dehydrogenase 2 (ALDH2) is an important mitochondrial aldehyde oxidase with multiple enzymatic functions, such as dehydrogenase and esterase, and is abundantly expressed in heart, liver, and brain tissues [15]. ALDH2 converts toxic acetaldehyde to non-toxic acetic acid during alcohol metabolism and prevents the accumulation of toxic aldehydes (e.g., 4-HNE and MDA) in tissues, thereby ameliorating toxic aldehydes’ effects on intracellular oxidative stress and mitochondrial function [16]. In recent years, an increasing number of studies have shown that ALDH2 is not only involved in alcohol metabolism but also plays an important role in many cardiovascular diseases, including cardiac hypertrophy, heart failure, myocardial ischemia-reperfusion injury, cardiac arrhythmias and atherosclerosis [17]. The available findings suggest that ALDH2 plays an integral role in the pathogenesis of cardiac remodeling. Consequently, the search for compounds that modulate ALDH2 and the elucidation of their regulatory mechanisms are of great importance in order to inhibit the progression of myocardial hypertrophy and heart failure diseases. Antrodia cinnamomea (AC) is a medicinal mushroom that grows on aromatic tree Cinnamomum kanehirai in Taiwan and is used by Taiwan's indigenous people as a traditional herbal remedy for hangovers and for treating ailments such as abdominal pain, hypertension and liver cancer [18]. AC extract mainly includes polysaccharides, steroids, triterpenoids, benzenes, and other components, among which triterpenoids (ACT) are its main active ingredients, including ergosterol triterpenes and lanostane triterpenes [19]. Whole extracts and active compounds of AC produce various biological activities, such as anti-tumor, anti-inflammatory, liver protection, immunomodulation, and antioxidant stress effects [20]. AC has a low level of toxicity and the products of AC have been marketed as health care products in China. Our preceding investigation revealed that AC elevated ALDH2 activity to protect against alcoholic liver injury and non-alcoholic fatty liver disease (NAFLD), indicating that ALDH2 might serve as a prospective target for AC to elicit pharmacological effects [21,22]. Nevertheless, the precise molecular mechanism by which AC and its monomer regulate the activity of the ALDH2 enzyme remains unclear. Furthermore, there is currently no literature examining the preventive and therapeutic effects of AC and its monomers on cardiac hypertrophy. Consequently, the aim of the present study was threefold: firstly, to elucidate whether ACT and its monomer exert an inhibitory effect on cardiac hypertrophy; secondly, to ascertain the relationship between their anti-hypertrophic effect and ALDH2; and thirdly, to explore the molecular mechanism by which ACT monomer regulate ALDH2 expression and enzyme activity. Here, we found that in a mice model of cardiac hypertrophy established by Angiotensin II (Ang II) and TAC, ACT administration attenuated the hypertrophic phenotype by inhibiting elevated levels of oxidative stress in the myocardium and modulating the MQC. Furthermore, it was demonstrated that these effects were mediated by ALDH2. In the Ang II-induced cardiomyocyte hypertrophy model of neonatal cardiac myocytes (NRCMs), both ACT and the active monomer DSA were observed to resist cardiomyocyte hypertrophy in an ALDH2-dependent manner. In a model of Ang II-induced hypertrophy in NRCMs, ACT and DSA were observed to inhibit cardiomyocyte hypertrophy through upregulation of ALDH2 mRNA and protein levels. Through “target fishing”, cellular thermal shift assay (CETSA) and overexpression/knockdown experiments in NRCMs, our study preliminarily explored the molecular mechanism by which DSA upregulates ALDH2 transcriptional levels. Materials and methods Chemicals Antrodia Cinnemomea triterpenoids were kindly provided by Prof. Yangchang Wu from Kaohsiung Medical University. Angiotensin II was purchased from Sigma-Aldrich (USA). Fetal bovine serum (FBS), Dulbecco's modified eagle's medium (DMEM), trypsin and collagenase type IV were purchased from Gibco (Grand Island, USA). Tissue-Tek O·C.T. compound was purchased from Sakura Finetek Japan Co., Ltd. (Tokyo, Japan). Mitochondrial aldehyde dehydrogenase activity assay kit (ab115348) was purchased from Abcam (Cambridge, England). 4-Hydroxynonenal (4-HNE) ELISA Kit (H268) was purchased from Nanjing Jiancheng Bioenginieering Insitute (Nanjing, China). Mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), rabbit anti-Drp1 primary antibodies, and horseradish peroxidase (HRP)-conjugated secondary antibodies were all purchased from Santa Cruz (Dallas, USA). Rabbit anti-ALDH2 primary antibodies were purchased from Abcam (Cambridge, UK). Rabbit anti-Mfn1, rabbit anti-Mfn2, rabbit anti-pink1, and rabbit anti-parkin were purchased from Proteintech Co., Ltd. (Wuhan, Hubei). Penicillin, streptomycin, MTT, gelatin, and all other reagents were purchased from Sigma-Aldrich (Beijing, China). Bexarotene was purchased from MedChemExpress (Shanghai, China). SNW1 plasmid, His-tag antibody and SNW1 antibody were kindly provided by the Qiao Zhang laboratory (Institute of molecular and medical virology, school of medicine, Jinan University). Ethics of animal experiments Healthy 8 to 10-week-old male C57BL/6 mice were obtained from the Department of Laboratory Animal Science, Peking University Health Science Center (Beijing, China). ALDH2−/− mice in C57BL/6 background were kindly provided by Prof. Aijun Sun from Zhongshan Hospital, Fudan University. Mice were housed in open-top conventional cages with poplar bedding material along with appropriate environmental enrichment with specific pathogen-free. A maximum of five mice were housed in a single cage. All mice were exposed to a 12 h light/dark cycle under defined environmental conditions at 25 ± 2 °C with a relative humidity of 50 % and were given free access to food and water. All animal care and experimental procedures complied with the Animals (Scientific Procedures) Act 1986 and all procedures involving animals were confirmed to the Regulations for the Administration of Affairs Concerning Experimental Animals published by the State Science and Technology Commission of China. The Biomedical Ethics Committee of Peking University approved in vivo and in vitro experiments in this study (Permit Number: LA2017120). Ang II-induced cardiac hypertrophy in mice The mice were anesthetized by injection of sodium pentobarbital and Ang II (3.0 mg·kg-1·d-1; Sigma, St. Louis, MO) or saline was administered via subcutaneously implanted osmotic mini-pumps (Model 1002, Durect, Cupertino, CA) as described previously [23]. Briefly, the mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg) and placed in a prostrate position on the animal operating table. Swab and wipe the shaved areas with betadine followed by three wipes with 70 % ethanol. Use a surgical scalpel to make an up to 1 cm incision behind the ear over the shoulder blade of the front leg. And make a subcutaneous tunnel under the skin using a hemostat. Then advance the hemostat tip toward the tail, and create a pocket for the pump, followed by inserting the pump into the incision with the moderator head positioned to the rear of the mouse and sutured. TAC-induced cardiac hypertrophy in mice The mice were anesthetized with an intraperitoneal injection of ketamine (120 mg/kg) and xylazine (6.2 mg/kg), before undergoing either a sham operation or TAC. TAC was performed as follows. The mice were intubated with an endotracheal tube connected to a rodent ventilator. After exposure of the aortic arch, the thymus was removed. The transverse aortic arch was then ligated between the brachiocephalic and left common carotid arteries with a 7-0 silk suture and a placing 27 G needle. Mice in the sham surgery group underwent the same operation, with the omission of aorta ligation. Administration regimens Part I. To explore the effects of ACT on Ang II-induced cardiac hypertrophy, the mice were randomly assigned to the Control group (Control), Ang II-induced model group (Ang II), and ACT group (Ang II + ACT). Mice in the Vehicle and the Ang II groups were orally administered with 200 μL 0.5% carboxymethylcellulose sodium (CMC-Na) once per day; the Ang II + ACT group received ACT treatment at a dose of 200 mg/kg by oral administration once a day for two weeks. Treatment in ALDH2−/− mice was the same as in the WT mice. Part II. To explore ACT anti-cardiac hypertrophy efficacy in a TAC model, the mice were randomly divided into the Sham group (Sham), TAC group (TAC), and TAC with ACT group (TAC + ACT). Mice in the Sham and TAC groups were orally administered with 200 μL 0.5% CMC-Na once per day; the TAC + ACT group received ACT treatment at a dose of 200 mg/kg of body weight by oral administration once per day beginning on the next day of TAC operation and lasting for three weeks. All animals were fed with a standard chow diet. Treatment in ALDH2−/− mice was the same as in the WT mice. At the end of the administration, all mice were sacrificed with an overdose of sodium pentobarbital. The ratio of heart weight to body weight (HW/BW), as well as the ratio of heart weight to tibia length (HW/TL), were used to evaluate cardiac hypertrophy; HE staining for detection of pathological changes in the myocardium of mice; Real-time PCR was conducted to test the mRNA expression of the fetal cardiac genes to explicit the anti-hypertrophic effects of ACT and clarify the mechanism of ACT. Histological analysis Hearts were collected immediately following sacrifice and fixed with 4 % formalin at room temperature for 24 h. Tissues were embedded with paraffin and cut into 5 μm-thick sections, and then stained with HE as previously described [24]. Isolation of NRCMs NRCMs were isolated from the ventricles of 1-day post-born Sprague-Dawley rats. Neonatal rats were provided by the Department of Laboratory Animal Science, Peking University Health Science Center (Beijing, China). Briefly, rats were disinfected with 70 % ethanol and then euthanized by cervical dislocation. The hearts were rapidly removed and placed in an ice-cold PBS. Ventricles were separated and minced with fine forceps. Tissue fragments were digested in 0.25 % trypsin for 25 min in a conical tube at 37 °C. After digestion, the cell suspension was centrifuged (250×g for 15 min at 4 °C). The pellet was resuspended in a culture medium (DMEM, supplemented with 10 % FBS). This cell suspension was pre-plated in a 10 cm culture dish at 37 °C for 90 min to enrich the culture with cardiac myocytes. The non-adherent myocytes were collected and cells were counted and then plated in 6-well plates. Cell culture and treatment NRCMs were maintained in a DMEM medium containing 10 % FBS, penicillin (100 μg/mL), and streptomycin (100 μg/mL) at 37 °C with 5 % CO2. To establish an in vitro hypertrophy cardiomyocyte model, NRCMs were starved in the 2 % FBS medium for 12 h and then subjected to 1 μM Ang II for 48 h, and the NRCMs were also simultaneously treated with ACT (25 μg/mL)/DSA (25 μM). Measurements of ALDH2 activity Heart tissues from each mouse group were weighed, put into EP tubes containing 1 mL of precooled PBS, homogenated for 15 s, centrifugated for 30 min, and then the supernatant was aspirated. The activity of the ALDH2 enzyme was measured using an ALDH2 activity assay kit (ab115348). The activity of ALDH2 was determined by monitoring the conversion of nicotinamide adenine dinucleotide (NAD+) to NADH at an absorbance of 450 nm using a microplate reader. Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay for cell viability The NRCMs were cultured in 96-well plates (1 × 104 cells/well) for 24 h. The cells were then treated with different concentrations of ACT or compound DSA for 24 h. After treatment, MTT was added to each well to a final concentration of 0.5 mg/mL and incubated for 4 h at 37 °C in a humidified incubator containing 5 % CO2. Then 200 μL DMSO was used to dissolve formazan and absorbance at 490 nm was measured with an ELISA reader (No.550, Hercules, California, USA). Lentivirus transfection of NRCMs NRCMs were inoculated in 24-well plates (104 cells per well) and cultured in DMEM supplemented with polybrene (V/V = 1:2000). Lentivirus ALDH2-KD or lentivirus ALDH2-OE (6 μL) was added into each well. After incubation with lentivirus for 12 h, the medium was discarded and the cells were incubated with DMEM for 72 h (the medium was replaced with fresh DMEM every day). After then, the medium was aspirated and the cells were incubated with DMEM containing puromycin (2 μg/mL) for 12 h, then the medium was removed. Finally, the cells were incubated with DMEM supplemented with 10 % FBS and 1 % penicillin-streptomycin for 24 h. ALDH2 overexpression and knockdown were validated using Western blot analysis. Transient transfection Transient transfection was performed using Lipofectamine 3000 reagent according to the manufacturer's instructions. Briefly, NRCMs were seeded to achieve a confluency of 70 % the following day. Plasmids or siRNA were transfected using Lipofectamine 3000 reagent (Thermo Fisher Scientific) separately in Opti-MEM. The cells were incubated with transfection complexes for 6 h. Then, the medium was replenished and the cells were harvested 24/48 h after transfection. Real-time PCR (RT-PCR) analysis Total RNA was extracted from tissues or cells using Trizol Reagent (Molecular Research Center, USA) and cDNA synthesis was performed using the TransScript First-Strand cDNA Synthesis Super Mix (TransGen Biotech). SYBR qPCR MasterMix (TransGen Biotech) was used to evaluate mRNA expression levels according to the manufacturer's instructions. The primers used for RT PCR are shown in Table S1. Transcription levels were normalized to internal control of β-actin in the tissues or GAPDH in the cells. Western blot assay Tissues or cells were collected and protein concentrations were quantified with a biscinchonic acid (BCA) kit (Pierce Biotechnology, Rockford, IL, USA). For Western blot, 30 μg of protein was loaded in each well and resolved by 10 % SDS-PAGE, and the protein bands were then electro-transferred onto a polyvinylidene difluoride membrane using the Bio-Rad MiniProtean II apparatus (Bio-Rad Laboratories, Carlsbad, CA, USA). The blots were subsequently incubated with anti-rabbit ALDH2 (1:1000), anti-rabbit Mfn1 (1:1000), anti-rabbit Mfn2 (1:100), anti-rabbit Drp1 (1:2000), anti-rabbit Pink1 (1:2000), anti-rabbit Parkin (1:2000), anti-rabbit SNW1(1:1000), anti-His tag (1:5000), and anti-mouse GAPDH (1:5000) at 4 °C overnight followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000) for 1 h and visualized with enhanced chemiluminescence system (Pierce Biotechnology, Rockford, IL, USA). GAPDH was used as an internal control for data normalization. All bands were quantified by Image J software. Identification of DSA's target The target protein of DSA was identified by human protein microarray at room temperature. Commercial HuProt proteome microarray was blocked with blocking buffer (3 % bovine serum albumin (BSA) in PBS) for 1 h at room temperature. Bio-DSA (10 μM) was used to incubate with the proteome microarray at room temperature for 1 h in a reaction buffer (1 % BSA in PBS). The microarray was washed with PBS three times, followed by incubation with Cy3-conjugated streptavidin at a 1:1000 dilution for 1 h. The microarray was then spun dry, and bio-DSA-protein interactions were detected with a GenePix 4200 A microarray scanner (Axon Instruments) at 635 nm. Data were analyzed using GenePix Prospector software (version 6.0). Cellular thermal shift assay (CETSA) For cellular thermal shift assay, NRCMs with 70–80 % confluence in a 15-cm culture dish were treated with DSA or vehicle (DMSO) for 1 h. The cells were harvested and washed once with PBS, then suspended in 1 mL of PBS supplemented with proteinase and phosphatase inhibitors, and also maintained with the same dose of compound DSA or DMSO as the initial treatment. The cell suspension was distributed into seven to ten 0.2-mL PCR tubes with 100 μL volume and each tube was designated a temperature point. Samples were heated at their designated temperatures for 5 min. Immediately after heating, tubes were removed and incubated at room temperature for 3 min. After the incubation, tubes were immediately snap-frozen in liquid nitrogen and stored at −80 °C. To lyse the cells, three freeze and thaw cycles in liquid nitrogen were performed. The tubes were vortexed briefly after each thawing. The cell lysates were collected and cell debris together with precipitated and aggregated proteins were removed by centrifuging samples at 15,000 rpm for 15 min at 4 °C. The cell lysate samples were then boiled for 5 min at 95 °C after the addition of loading buffer, and subjected to Western blot analysis. Statistical analysis All data are presented as mean ± SEM. P < 0.05 was considered as statistical significance of difference. The statistical significance of differences among the groups was analyzed by one-way ANOVA for multiple comparisons with a Tukey test. Tukey tests were run only when F achieved P < 0.05 and there was no significant variance inhomogeneity. All statistical analyses were performed using GraphPad Prism for Windows (San Diego, CA, USA). Results ACT attenuates Ang II-induced cardiac hypertrophy and oxidative stress and improves impaired MQC in NRCMs The safe doses of ACT for NRCMs were determined by treating with 12.5–100 μg/mL ACT for 48 h. The results of the MTT assay found that the concentrations of ACT less than 25 μg/mL exhibited no significant toxic effects on NRCMs (Fig. 1a). Ang II treatment for 48 h resulted in a significant increase in the gene expression of atrial natriuretic factor (Anf), brain natriuretic peptide (Bnp) and β-myosin heavy chain (β-MHC) (Fig. 1b–d). In comparison to the Ang II group, ACT treatment of NRCMs was observed to result in a notable reduction in Ang II-induced mRNA levels of Anf, Bnp, and β-MHC (Fig. 1b–d). ACT attenuates Ang II-induced hypertrophic response and mitochondrial dysfunction in NRCMs. (a) MTT assay for detecting the cytotoxicity of ACT on NRCMs. (b–d) RT-PCR to analyze the mRNA expressions of Anf, Bnp, and β-MHC induced by Ang II. (e–g) RT-PCR to analyze the mRNA expressions of Nox-4, Nrf-2, and HO-1 induced by Ang II. (h) Western blot to detect the protein expressions of Mfn1, Mfn2, Drp1, Pink1, and Parkin. (i–j) Quantitative analysis of Mfn1, Mfn2, Drp1, Pink1 and Parkin. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) In addition, Ang II treatment induced a significant oxidative stress response in NRCMs. This response was evidenced by an up-regulation of the mRNA levels of genes involved in oxidative stress, including Nox-4, and a down-regulation of the mRNA levels of genes that act as antioxidants, including Nrf2 and HO-1 (Fig. 1e–g). Ang II treatment also impaired MQC in NRCMs, as shown in Fig. 1h–j. Specifically, there was an increase in the expression of the mitochondrial fission protein Drp1, a decrease in the expression of the mitochondrial fusion proteins Mfn1 and Mfn2, and a further reduction in the expression of the mitochondrial autophagy proteins Pink1 and Parkin. As anticipated, ACT treatment effectively suppressed Ang II-induced oxidative stress and restored the impaired MQC by reducing mitochondrial fission and promoting mitochondrial fusion and mitophagy (Fig. 1h–j). ACT and its monomer DSA attenuate Ang II-induced cardiac hypertrophy in NRCMs in an ALDH2-dependent manner The ACT contains more than 70 monomer components, among which monomer DSA, a lanolin alkane-type triterpene, was identified as exhibiting high activity with minimal toxicity through our screen. Its chemical structural representation is presented in Fig. 2a. To ascertain whether DSA could be considered as a representative active monomer of ACT with an inhibitory effect on cardiomyocyte hypertrophy, we applied the Ang II-induced cell model to validate this hypothesis. In NRCMs, DSA was observed to have a low toxicity property and to significantly inhibit the upregulation of hypertrophy-related genes (Anf and Bnp mRNA levels) induced by Ang II at a dose of 25 μM (Fig. 2b–d). ACT and its active monomer DSA attenuate Ang II-induced hypertrophic responses in NRCMs in an ALDH2-dependent manner. (a) Chemical structure of DSA. (b) MTT assay for detecting the cytotoxicity of DSA on NRCMs. (c–d) RT-PCR to analyze the mRNA expressions of Anf and Bnp induced by Ang II. (e–f) Western blot to verify and quantify the overexpression and knockdown efficiency of ALDH2. (g–h) After overexpression and knockdown of ALDH2 by lentivirus, the mRNA levels of Anf and Bnp in NRCMs induced by Ang II were detected by RT-RCR. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus Control group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus Ang II group; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; &&p < 0.01, &&&p < 0.001). To further elucidate the potential role of ALDH2 in mediating the anti-hypertrophic effects of ACT and DSA, we employed a lentivirus-based approach to overexpression or knockdown ALDH2 expression in NRCMs (Fig. 2e–f), and the effects of Ang II-induced hypertrophy and the efficacy of ACT and DSA were subsequently evaluated in this context. As shown in Fig. 2g–h, the Ang II-induced hypertrophic response was absent in NRCMs overexpressing ALDH2. In NRCMs with knockdown of ALDH2, it was observed that hypertrophy genes could be significantly up-regulated in NRCMs even without Ang II inducement. Furthermore, ACT/DSA was unable to reverse the Ang II-induced hypertrophic responses in the ALDH2 deficient NRCMs (Fig. 2g–h). ALDH2 mediates the anti-cardiac hypertrophic effects of ACT in the Ang II-induced mouse model To ascertain whether ACT exerts the potential cardio-protective effects, we established a cardiac hypertrophy model by subcutaneously implanting an Ang II infiltration pump in WT mice and observed whether ACT inhibited cardiac hypertrophy by gavage of either ACT (200 mg/kg) or vehicle (0.5 % CMC-Na). In comparison to the WT-Control group, the WT-Ang II group exhibited a significant increase in the HW/BW, the HW/TL, and the ventricular chambers exhibited significant dilatation, all of which were significantly attenuated in the WT- Ang II + ACT group (Fig. 3a–c). The results of RT-PCR demonstrate that expression of fetal genes such as Anf, Bnp and β-MHC were significantly up-regulated in the WT-Ang II group, and ACT reduced the expression of hypertrophic pathological phenotypes, which was accompanied by the down-regulation of hypertrophic genes of Anf, Bnp and β-MHC (Fig. 3d–f). ALDH2 mediates the anti-cardiac hypertrophic effects of ACT in the Ang II-induced mouse model. (a) H&E staining of mouse heart tissues. (b) Quantitative analysis of HW/BW. (c) Quantitative analysis of HW/TL. (d–f) RT-PCR to analyze the mRNA expressions of Anf, Bnp and β-MHC in the heart tissues of WT mice. (g–i) RT-PCR to analyze the mRNA expressions of Anf, Bnp and β-MHC in the heart tissues of ALDH2−/− mice. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Based on the in vitro evidence indicating that ALDH2 plays a pivotal role in the inhibitory effect of ACT and DSA on cardiomyocyte hypertrophy, we proceeded to investigate whether the inhibitory effect of ACT on cardiac hypertrophy observed in Ang II-induced mice was related to ALDH2. To this end, we conducted a further study to examine the effects of ACT on ALDH2−/− mice. ALDH2−/− mice exhibited severe cardiac hypertrophy after induction by Ang II. However, no ameliorative effect was observed after treatment with ACT. In particular, ACT did not mitigate the Ang II-induced ventricular dilatation, it also failed to inhibit the elevation in the ratio of HW/BW and HW/TL in ALDH2−/− mice (Fig. 3a–c). Furthermore, it demonstrates no inhibitory effects on the up-regulation of fetal genes related to cardiac hypertrophy, including Anf, Bnp, and β-MHC (Fig. 3g–i). ALDH2 mediates the anti-cardiac hypertrophic effects of ACT in the TAC-induced mouse model We proceeded to establish a model of pressure overload-induced cardiac hypertrophy (TAC-operated) in WT and ALDH2−/− mice, with a further objective of confirming whether ALDH2 is involved in the anti-hypertrophic effect of ACT. In WT mice, we observed a significant TAC-induced thickening of the ventricular wall and elevated levels of HW/BW, HW/TL and hypertrophy-associated fetal genes. However, these effects were significantly attenuated by gavage with ACT (200 mg/kg) (Fig. 4a–f). In normal conditions, ALDH2−/− mice exhibited a tendency towards increased HW/BW and HW/TL ratios compared with WT mice. However, ALDH2 deficiency appeared to exacerbate the increase in HW/BW and HW/TL ratios following TAC induction compared with WT-TAC mice (Fig. 4b–c). Nevertheless, ACT did not result in a reduction in the HW/BW and HW/TL ratios or mRNA levels of Anf, Bnp, and β-MHC in ALDH2−/−-TAC mice, nor did it lead to an attenuation of ventricular wall thickness (Fig. 4a–c, g-i). In both the ACT-treated and the vehicle-treated groups, a deterioration in cardiac hypertrophy was observed in the ALDH2−/−-TAC mice. The results obtained in the TAC model were found to be consistent with those observed in the Ang II model, indicating that the anti-cardiac hypertrophy effect of ACT is primarily mediated by ALDH2. ALDH2 mediates the anti-cardiac hypertrophic effects of ACT in the TAC-induced mouse model. (a) H&E staining of mice heart tissues. (b) Quantitative analysis of HW/BW. (c) Quantitative analysis of HW/TL. (d–f) RT-PCR to analyze the mRNA expressions of Anf, Bnp, and β-MHC in the heart tissues of WT mice. (g–i) RT-PCR to analyze the mRNA expressions of Anf, Bnp, and β-MHC in the heart tissues of ALDH2−/− mice. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). ALDH2 mediates the effects of ACT on the attenuation of oxidative stress and improvement of impaired MQC in the cardiac hypertrophy mice Given the pivotal regulatory function of ALDH2 in mitochondrial oxidative stress and MQC, which in turn affects the pathological process of cardiac hypertrophy, The levels of oxidative stress and MQC-related genes and proteins were examined in myocardial tissues from the mice with cardiac hypertrophy. As illustrated in Fig. 5a, a notable elevation in myocardial ROS levels was observed in the WT- Ang II group, while a substantial reduction in ROS accumulation was evidenced in the WT- Ang II + ACT group. ACT was similarly observed to significantly reduce myocardial ROS accumulation in WT-TAC-induced cardiac hypertrophic mice (Fig. 5b). Furthermore, we observed a significant down-regulation of oxidative stress-related genes (SOD1, SOD2, Nrf2, and HO1) in the WT-Ang II group, which was reversed by the ACT treatment (Fig. 5c). In ALDH2−/− mice, the induction of myocardial ROS accumulation following TAC surgery and Ang II osmotic pump was more pronounced, as evidenced by a significant up-regulation of 4-HNE levels and a significant down-regulation of mRNA levels of genes related to anti-oxidative stress (Fig. 5a, b, d). However, the effect of ACT on the attenuation of myocardial ROS accumulation induced by Ang II and TAC was absent in the ALDH2−/− mice (Fig. 5a, b, d). ALDH2 mediates the effects of ACT in the attenuation of oxidative stress in cardiac hypertrophy model. (a) 4-hydroxynonenal levels in the heart tissues of the Ang II-induced WT and ALDH2 −/− mice. (b) 4-hydroxynonenal levels in the heart tissues of the TAC-induced WT and ALDH2 −/− mice. (c) In WT mouse myocardial tissues, RT-PCR to detect mRNA levels of SOD-1, SOD-2, Nrf-2, and HO-1 in the Ang II-induced mouse model. (d) In ALDH2−/− mouse myocardial tissues, RT-PCR to detect mRNA levels of SOD-1, SOD-2, Nrf-2, and HO-1 in the Ang II-induced mouse model. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). The protein expression levels of mitochondrial dynamics and autophagy were examined in the mouse myocardial tissues. The results revealed that in the WT-Ang II group, the expression of the mitochondrial fusion proteins Mfn1 and Mfn2 and mitochondrial autophagy proteins Pink1 and Parkin was decreased, and the expression of the mitochondrial fission protein Drp1 was increased (Fig. 6a–c). As expected, ACT treatment increased mitochondrial fusion, decreased mitochondrial fission, and promoted mitochondrial autophagy (Fig. 6a–c). To further investigate the role of ALDH2 in the maintenance of MQC by ACT, we also examined the expression levels of related proteins in ALDH2−/− mice. Our results showed that the expression of the fusion proteins (Mfn1 and Mfn2) and the mitophagy proteins (Pink1 and Parkin1) remained down-regulated, and the fission protein Drp1 was significantly up-regulated, but no significant differences were observed between the Ang II group and ACT-treated Ang II group in the ALDH2−/− mice (Fig. 6d–f). These findings indicate that ACT was unable to improve MQC impairment in the Ang II-induced ALDH2−/− mice. Taken together, these data suggest that ACT improves Ang II- and TAC-induced MQC impairment in an ALDH2-dependent manner. ALDH2 mediates the effects of ACT in the improvement of MQC impairment in the cardiac hypertrophy mouse model. (a) In the WT mouse myocardial tissues, Western blot to detect the protein expressions of Mfn1, Mfn2, Drp1, Pink1, and Parkin in the Ang II-induced mice. (b–c) Quantitative analysis of Mfn1, Mfn2, Drp1, Pink1, and Parkin. (d) In the ALDH2−/− mouse myocardial tissues, Western blot to detect the protein expressions of Mfn1, Mfn2, Drp1, Pink1, and Parkin in the Ang II-induced mice. (e–f) Quantitative analysis of Mfn1, Mfn2, Drp1, Pink1 and Parkin. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) ACT up-regulates ALDH2 expression and activity in vivo and in vitro We then sought to further elucidate the specific regulation of ACT on ALDH2. Examination of mRNA levels revealed a significant down-regulation of ALDH2 mRNA levels in the mouse heart tissues after induction of the cardiac hypertrophy by Ang II and TAC, whereas ALDH2 mRNA levels were significantly up-regulated after ACT treatment (Fig. 7a–e). The reversal of Ang II-induced down-regulation of ALDH2 mRNA levels by ACT and the active monomer DSA was also observed in NRCMs (Fig. 7h). In terms of protein levels, ALDH2 expression was diminished in the heart tissues of Ang II- and TAC-induced mice, compared to the Control/Sham group, and ACT significantly up-regulated ALDH2 protein levels (Fig. 7b–c, f-g). In vitro experiments, Ang II significantly down-regulated ALDH2 protein levels, while ACT and DSA restored ALDH2 protein levels in NRCMs (Fig. 7i–j). Previous studies have indicated that the ALDH2 active site contains redox-sensitive sulfhydryl groups and that an increase in oxygen radicals in the body promotes the formation of disulfide bonds in the ALDH2 active site and inactivates it[25]. Following the detection of ALDH2 activity levels in mice myocardial tissues, it was observed that ALDH2 activity in the Ang II group was significantly reduced in comparison to that in the Control group (Fig. 7d). Furthermore, it was demonstrated that ACT treatment significantly increased ALDH2 activity (Fig. 7d). ACT up-regulates ALDH2 expression and activity in vivo and in vitro. (a) RT-PCR to analyze the mRNA levels of cardiac ALDH2 in the Ang II-induced cardiac hypertrophy mice. (b–c) Western blot to detect and quantify cardiac ALDH2 protein levels in the Ang II-induced cardiac hypertrophy mice. (d) Quantitative analysis of cardiac ALDH2 activity in the Ang II-induced cardiac hypertrophy mice. (e) RT-PCR to analyze the mRNA levels of cardiac ALDH2 in the TAC-induced cardiac hypertrophy mice. (f–g) Western blot to detect and quantify cardiac ALDH2 protein levels in the TAC-induced cardiac hypertrophy mice. (h) RT-PCR to detect the mRNA level of ALDH2 in NRCMs on the Ang II-induced hypertrophy cell model. (i–j) Western blot to detect and quantify the protein level of ALDH2 in NRCMs on the Ang II-induced hypertrophy cell model. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01). SNW1 as a binding protein of DSA is involved in regulating ALDH2 expression The anti-hypertrophic effects observed for ACT and its active monomer DSA are due to the action of ALDH2, with ACT being observed to significantly increase ALDH2 expression and activity. It is therefore hypothesized that ALDH2 may be the target for the anti-hypertrophic effects of ACT and DSA. We then used the CETSA to determine whether DSA could improve the thermal stability of the ALDH2 protein. However, our results indicated that DSA was unable to achieve this goal (Figs. S1a–b). Furthermore, the surface plasmon resonance (SPR) assay also failed to detect any binding effect between DSA and ALDH2 (Fig. S1c). The aforementioned results indicate that DSA exerts antihypertrophic effects probably through indirectly regulating ALDH2. To identify the key molecules regulating ALDH2 expression, a biotin-labeled DSA molecular probe was constructed and used to detect the HuProt proteome microarray. Data from “target fishing” identified 57 binding proteins with a z-score greater than 1, but no transcription factors were identified that directly regulate ALDH2 transcript levels. We subsequently focused our attention on the role of cofactors in the transcription complex. Our findings revealed that SNW1, a binding protein to DSA, typically encodes a coactivator that enhances transcription from specific Pol II promoters. This process allowed the identification of the SNW1 as a binding protein of DSA (Fig. 8a). In addition, we determined the target engagement of DSA by using the CETSA. Treatment of NRCMs with DSA resulted in increased thermal stabilization of the SNW1 protein, suggesting binding between DSA and SNW1 (Fig. 8b). SNW1 as a binding protein for DSA is involved in regulating ALDH2 expression. (a) CETSA assay confirmed the binding of DSA to SNW1 in NRCMs, and GAPDH was used as the internal control. (b) The graph shows the quantification of SNW1 protein versus temperature points based on Western blot analyses. (c–e) Western blot to detect and quantify His-tag and ALDH2 protein levels in NRCMs after overexpression of SNW1. (f–h) Western blot to detect and quantify SNW1 and ALDH2 protein levels in NRCMs after knockdown of SNW1. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Given the precise function of SNW1 in the heart is unclear, and its role in the regulation of ALDH2 is unknown. Consequently, we sought to further investigate the potential role of SNW1 in regulating ALDH2 expression. To this end, we performed SNW1 overexpression and knockdown in NRCMs, respectively. The results showed that SNW1 overexpression resulted in a significant increase in ALDH2 protein levels, while SNW1 knockdown resulted in a significant decrease in ALDH2 expression (Fig. 8c–h). SNW1 regulates ALDH2 expression by co-operating with RXR SNW1 acts as a transcriptional co-activator that binds to the ligand-binding domain of the Vitamin D receptor and to retinoid receptors to enhance Vitamin D-, retinoic acid-, estrogen-, and glucocorticoid-mediated gene expression. Furthermore, previous studies have identified retinoic X receptors (RXRs) response elements within the ALDH2 promoter region, which are known to mediate transcription. Retinoic X-mediated signaling has been reported to inhibit cardiac hypertrophy and fibrosis. Therefore, we considered SNW1, as a transcriptional coactivator, to regulate ALDH2 expression through RXRs. Firstly, treatment of NRCMs with the selected RXR agonist, bexarotene, significantly up-regulated ALDH2 mRNA and protein levels (Fig. 9a–c). To further clarify the role of SNW1 in the regulation of ALDH2 expression by RXR, we performed bexarotene treatment based on SNW1 knockdown and observed the changes in ALDH2 expression levels. The results demonstrate that in the context of SNW1 knockdown, the treatment of bexarotene was ineffective in up-regulating ALDH2 mRNA and protein levels (Fig. 9d–h). Taken together, these results suggest that DSA plays a role in up-regulating ALDH2 expression probably through SNW1/RXR transcription complex. SNW1 regulates ALDH2 expression by co-operating with RXR. (a) RT-PCR to detect ALDH2 mRNA levels in NRCMs following the administration of bexarotene. (b–c) Western blot to detect and quantify ALDH2 protein levels in NRCMs following the administration of bexarotene. (d) RT-PCR to detect the mRNA level of SNW1 in NRCMs after knockdown of SNW1. (e) RT-PCR to detect the mRNA level of ALDH2 in NRCMs after administration of bexarotene, following knockdown of SNW1. (f) Western blot to detect the protein levels of SNW1 and ALDH2 in NRCMs after administration of bexarotene, following knockdown of SNW1. (g–h) Quantitative analysis of SNW1 and ALDH2. (Mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Discussion Pathological cardiac hypertrophy is not only a major component in the pathogenesis of heart failure, but also a hallmark of several cardiovascular diseases [26]. Despite significant progress in recent years in the identification of key molecular targets and signaling pathways in pathological cardiac hypertrophy, current clinical medicinal interventions for the effective treatment of cardiac hypertrophy remain unsatisfactory [27]. Recently, there has been a growing interest among researchers in the potential of active ingredients derived from natural products, such as medicinal fungi, for the prevention and treatment of a range of cardiovascular diseases [28]. ACT is commonly employed in traditional folk medicine as a hangover remedy, and ALDH2 is a pivotal enzyme involved in alcohol metabolism. Our previous studies have demonstrated that ACT and monomers not only alleviate alcoholic fatty liver disease but also exert a pronounced inhibitory effect on the progression of non-alcoholic fatty liver disease. Moreover, our research indicates that the beneficial effects of ACT and monomers on both alcoholic and non-alcoholic fatty liver disorders are contingent upon ALDH2 [21,22]. In this study, we initially identified the anti-cardiac hypertrophy effects of ACT and monomeric DSA, with ALDH2 serving as a crucial mediator. Subsequent experiments found that ACT and DSA can upregulate the expression level of ALDH2. However, SPR and CETSA experiments revealed that DSA does not directly bind to ALDH2. To elucidate the specific mechanism by which DSA upregulates the transcription level of ALDH2, we conducted further screening of DSA binding proteins and identified that DSA can directly bind to SNW1, thereby upregulating the transcription level of ALDH2 through the SNW1/RXR transcription complex. This results in the upregulation of ALDH2 protein expression and enzyme activity of ALDH2, which plays an important role in reducing oxidative stress damage and maintaining MQC homeostasis. In conclusion, this study has provided preliminary insights into the novel pharmacological effects of ACT and DSA on cardiac hypertrophy and the underlying molecular mechanisms of ALDH2 regulation. It is well established that mitochondria play a pivotal role in maintaining myocardial energy requirement and ROS production [29]. In physiological conditions, the production of ROS by the electron transport chain is balanced by a range of anti-oxidant mechanisms within the mitochondria. However, in pathological conditions, the reduction in the activity of antioxidant enzymes results in oxidative damage and increased mitochondrial ROS production, which in turn leads to a reduction in mitochondrial content and an imbalance between fission and fusion processes[30]. Accumulating evidence indicates that aberrations in mitochondrial dynamics, resulting from elevated mitochondrial ROS production, contribute to the accumulation of dysfunctional mitochondria and the advancement of cardiovascular diseases [31]. Reducing ROS accumulation is crucial for reestablishing MQC homeostasis and preventing cardiac hypertrophy [32]. Accordingly, the effects of ACT on ROS production and the expression of mitochondrial fusion and fission-related proteins in cardiomyocytes and myocardial tissues were examined. The findings of this study demonstrate that ACT effectively suppressed the mRNA expression of NADPH oxidase-Nox 4 in Ang II-stimulated cardiomyocytes to attenuate excessive oxidative stress levels. Furthermore, ACT markedly elevated the mRNA levels of Nrf2, HO-1, SOD-1, and SOD-2 in Ang II-stimulated myocardial tissues and cardiomyocytes, contributing to ROS clearance. In addition, Ang II was observed to down-regulate the expression of mitochondrial fusion-associated proteins, including Mfn1 and Mfn2, in cardiomyocytes and myocardial tissues when compared with the control group. Conversely, the expression level of the mitochondrial fission protein Drp1 was found to be significantly elevated following Ang II stimulation. It is noteworthy that the ACT-treated group exhibited a notable increase in the expression of Mfn1 and Mfn2, while displaying a marked reduction in the expression level of Drp1, in comparison to the Ang II-treated group. The findings indicate that ACT suppressed ROS generation in cardiomyocytes and myocardial tissues under pathological circumstances while facilitating mitochondrial fusion and inhibiting mitochondrial fission. ACT protects mitochondria by restoring mitochondrial dynamics through the aforementioned effects, thereby contributing to the amelioration of cardiac hypertrophy. ALDH2, a pivotal enzyme in the metabolism of various aldehydes, is situated within the mitochondrial matrix and exerts a crucial influence on the modulation of oxidative stress and mitochondrial dysfunction. Recent studies have identified ALDH2 as a key contributor to the pathogenesis of pathological myocardial hypertrophy and heart failure by regulating oxidative stress and mitochondrial function [33]. In vivo experiments demonstrate that pharmacological activation or overexpression of ALDH2 had beneficial effects on stress-induced cardiac hypertrophy [34]. Conversely, diminished ALDH2 activity and expression hastened mitochondrial dysfunction, thereby fostering cardiac remodeling and cardiac dysfunction [35]. However, there is currently no evidence as to whether ACT regulates ALDH2 expression or activity contributing to the inhibitory effects of ACT on cardiac hypertrophy. The present study found that ALDH2 mRNA and protein levels and activity were all significantly enhanced in cardiac myocardial tissues of ACT-treated WT-Ang II/TAC mice. Furthermore, ACT was observed to significantly reduce 4-HNE content, up-regulate mRNA levels of anti-oxidant genes, and maintain MQC homeostasis in the myocardial tissues of WT-Ang II/TAC mice, which ultimately impeded the progression of cardiac hypertrophy. Subsequently, we constructed global ALDH2 knockout mice, which observed that 4-HNE levels in cardiac tissues were elevated and the HW/TL ratio exhibited a slight increase under normal conditions in comparison to the WT mice. Furthermore, the ALDH2−/− mice exhibited heightened cardiac oxidative stress levels and a more pronounced degree of Ang II- and TAC-induced cardiac hypertrophy compared to the WT-Ang II/TAC mice. Nevertheless, in ALDH2−/− -Ang II/TAC mice, ACT was observed to lose its capacity to inhibit oxidative stress in myocardial tissues, maintain MQC homeostasis, and ameliorate the degree of myocardial hypertrophy. Similarly, in NRCMs, we observed that ACT restored the mRNA and protein levels of ALDH2 in the presence of Ang II treatment. This resulted in a reduction in oxidative stress and the maintenance of MQC homeostasis, which ultimately inhibited cardiomyocyte hypertrophy. The knockdown of ALDH2 expression resulted in a significant up-regulation of the mRNA levels of Anf and Bnp. Furthermore, concomitant Ang II treatment led to a further exacerbation of cardiomyocyte hypertrophy. However, ACT was unable to exert its inhibitory effect on hypertrophy in the ALDH2 knockdown cardiomyocytes. Subsequently, in cardiomyocytes with ALDH2 overexpression, Ang II was unable to successfully induce cardiomyocyte hypertrophy. The aforementioned results indicate that ACT up-regulates ALDH2 expression and activity in pathological conditions of cardiac hypertrophy. Furthermore, ALDH2 maintains the homeostatic balance of mitochondrial dynamics by inhibiting oxidative stress, which in turn mediates the anti-cardiac hypertrophic effect of ACT. Given the pivotal function of ALDH2 in mediating the inhibitory effects of ACT on cardiac hypertrophy disease, we sought to further elucidate the mechanism of ACT in the regulation of ALDH2 expression. Consequently, the monomer-DSA, which exhibits low toxicity and high activity, was isolated from ACT for subsequent study. A paucity of literature on DSA studies has thus far been identified. A paper by Yao-Haur Kuo et al. reported that DSA inhibited α-glucosidase activity in vitro, thereby suggesting a potential antidiabetic effect of DSA [36]. Another study demonstrates that DSA diminished the rate of SARS-CoV-2 pseudovirus infection [37]. However, there are no reports in the literature to date on whether DSA has affected cardiac hypertrophy. Firstly, the results obtained from NRCMs demonstrate that DSA exerts anti-cardiomyocyte hypertrophic effects comparable to those seen with ACT. Moreover, DSA significantly enhanced the expression of ALDH2 at the mRNA and protein levels in the Ang II-induced cardiomyocytes. Furthermore, the inhibitory effects of DSA on cardiomyocyte hypertrophy were abrogated following ALDH2 knockdown in NRCMs, which was consistent with the results of ACT. The in vitro experiments indicate that DSA can function as an effective monomer of ACT to exert its anti-cardiac hypertrophic effects, with ALDH2 acting as a mediator of its effects. Regrettably, the low yield of DSA obtained through ACT extraction precluded the possibility of conducting in vivo experiments now. Thus, the objective of future studies is to further confirm the antihypertrophic effect of DSA in vivo and to validate whether DSA's effects are mediated by ALDH2 and through upregulating ALDH2 expression. Given that DSA can dramatically elevate the mRNA level of ALDH2, we conducted a screening of SNW1, a protein regulating gene transcription level, from the binding protein of DSA by the “target fishing” technique. Subsequently, the binding effect between DSA and SNW1 was validated through a CETSA assay. SNW1, also designated as SKI-interacting protein 1 (SKIP1), is a multifunctional protein that plays a role in transcriptional co-regulation, mRNA splicing, cell cycle progression, and inflammatory responses [38]. It has been reported that SNW1 acts as an important co-regulator of nuclear receptors, enhancing the expression of genes regulated by Vitamin D, retinoic acid, estrogen, and glucocorticoids [39]. However, there is no existing literature on whether SNW1 regulates ALDH2 expression, which therefore was elucidated in this study. Following the regulation of SNW1 in NRCMs, we observed that overexpression of SNW1 led to a significant elevation in ALDH2 protein level, while ALDH2 protein levels were significantly reduced by knockdown of SNW1. These findings indicate that SNW1, which binds to DSA, functions as a transcriptional co-activator, regulating the transcriptional level of ALDH2. The aforementioned results indicate that SNW1 may serve as a potential protective factor in the progression of cardiac hypertrophy. We will also investigate the role of SNW1 in cardiac hypertrophy and its potential as a promising target in future studies. Nuclear receptors serve a pivotal function as transcription factors, regulating ALDH2 transcript levels. Some studies have demonstrated that peroxisome proliferator-activated receptors (PPARs) exhibit high affinity for nuclear receptor response elements (NRREs) within the ALDH2 promoter region, with activation of PPARs resulting in increased ALDH2 mRNA expression and enzyme activity [40]. Retinoid receptor response elements have also been identified within the ALDH2 promoter region, suggesting a potential contribution of RXRs to the regulation of ALDH2 expression [41]. Furthermore, studies in spontaneously hypertensive rats have demonstrated that RXR agonist markedly inhibits left ventricular hypertrophy without influencing blood pressure [42]. Nevertheless, further investigation is required to ascertain whether RXRs exert their anti-cardiac hypertrophic effect via modulation of ALDH2. Prior research has demonstrated that SNW1 functions as a transcriptional co-activator, binding to RXR/VDR heterodimers. Additionally, the binding of SNW1 to RXR has been predicted in publicly accessible databases. Consequently, we investigated whether SNW1 regulates ALDH2 expression via the transcription factor RXR. The results demonstrate that the treatment of the RXR agonist bexarotene resulted in a dose-dependent up-regulation of ALDH2 mRNA and protein levels in NRCMs. Subsequently, the knockdown of SNW1 following bexarotene treatment resulted in the loss of the observed up-regulation of ALDH2 level. This indicates that SNW1 functions as a transcriptional co-activator, working with the transcription factor RXR to regulate ALDH2 expression. Conclusion In summary, this study indicates that ACT/DSA exerts its regulatory effects on ALDH2 through a mechanism involving SNW1/RXR co-regulation, thereby attenuating cardiac hypertrophy in an ALDH2-dependent manner. The findings will provide a basis for the development of new drugs to intervene in cardiac hypertrophy and offer insights into potential drug targets and pathways. CRediT authorship contribution statement Yinghua Ma: Formal analysis, Methodology, Writing – original draft, Writing – review & editing. Yunxia Wang: Formal analysis, Methodology, Software, Writing – original draft. Gulinigaer Anwaier: Formal analysis, Methodology, Software. Nuerbiye Tuerdi: Methodology, Project administration. Yangchang Wu: Investigation, Methodology. Yinyue Huang: Data curation, Methodology, Validation. Boyang Qin: Data curation, Methodology. Haoyue Ma: Methodology, Validation. Qiao Zhang: Investigation, Resources. Dalei Wu: Conceptualization, Formal analysis, Writing – original draft. Kewu Zeng: Investigation, Validation, Writing – review & editing. Rong Qi: Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – review & editing. Funding This research was supported by the National Natural Science Foundation of China (No. 82470436, 82170280 for Prof. RongQi), Beijing Natural Science Foundation (No. 7232093 for Prof. Rong Qi), the Jinan New 20 Policies for Higher Education Funding (202228048 for Prof. Kewu Zeng) and the Natural Science Foundation of Shandong Province (Joint Fundation for Innovation and Development) (ZR2022LZY021 for Prof. Kewu Zeng). Declaration of competing interest We declare that there are no conflicts of interest in relation to the manuscript titled “Antrodia Cinnamomea Triterpenoids Attenuate Cardiac Hypertrophy via the SNW1/RXR/ALDH2 axis” submitted to Redox Biology. We confirm that the results and interpretations reported in the manuscript are original and have not been plagiarized. We certify that we have read and understand the Redox Biology conflict of interest policy, and We understand that failure to disclose a conflict od interest may result in the manuscript being rejected or retracted. We also certify that I have disclosed any financial or non-financial relationships that may be interpreted as constituting a conflict of interest in relation to this manuscript. We understand that this information will be subject to peer review, and we are willing to provide further information or clarification if required. We confirm that We have no known conflicts of interest that would influence the results or interpretation of the data presented in this manuscript, and we understand the seriousness of not disclosing a conflict of interest. Acknowledgment We thank Prof. Aijun Sun (from Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai) for providing ALDH2−/− mice to this study. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2024.103437. Contributor Information Yinghua Ma, Email: cherry_research20@163.com. Rong Qi, Email: ronaqi@bjmu.edu.cn. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1